119 related articles for article (PubMed ID: 7967440)
41. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
Alderson MR; Sassenfeld HM; Widmer MB
J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
[TBL] [Abstract][Full Text] [Related]
42. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
43. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo.
Jantzer P; Schendel DJ
Cancer Res; 1998 Jul; 58(14):3078-86. PubMed ID: 9679974
[TBL] [Abstract][Full Text] [Related]
44. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
45. Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients.
Karimine N; Nanbara S; Arinaga S; Asoh T; Ueo H; Akiyoshi T
J Surg Oncol; 1994 Mar; 55(3):179-85. PubMed ID: 8176929
[TBL] [Abstract][Full Text] [Related]
46. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
47. Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas.
Tsukuda M; Mochimatsu I; Sakumoto M; Furukawa S; Yuyama S; Yanoma S; Kubota A
Biotherapy; 1993; 6(2):155-61. PubMed ID: 8398575
[TBL] [Abstract][Full Text] [Related]
48. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
49. Enhanced susceptibility of adriamycin-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes and tumor infiltrating lymphocytes.
Wu XX; Zeng Y; Jin XH; Kakehi Y
Oncol Rep; 2007 Aug; 18(2):353-9. PubMed ID: 17611656
[TBL] [Abstract][Full Text] [Related]
50. [Study of cytotoxicity of recombinant interleukin-2 (rIL-2) expanded tumor infiltrating lymphocytes (TIL) in renal cell cancer].
Nishimura T; Terashima Y; Hattori T; Satoh M; Watanabe J; Kimura G; Yoshida K; Akimoto M
Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):835-40. PubMed ID: 2402104
[TBL] [Abstract][Full Text] [Related]
51. Expression of cytokine mRNA transcripts in renal cell carcinoma.
Olive C; Cheung C; Nicol D; Falk MC
Immunol Cell Biol; 1998 Aug; 76(4):357-62. PubMed ID: 9723777
[TBL] [Abstract][Full Text] [Related]
52. Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides.
Kawashima H; Obayashi A; Kawamura M; Masaki S; Tamada S; Iguchi T; Uchida J; Kuratsukuri K; Tanaka T; Nakatani T
BJU Int; 2014 Feb; 113(2):320-32. PubMed ID: 24895689
[TBL] [Abstract][Full Text] [Related]
53. Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation.
Umezu Y; Augustus LB; Seito D; Hayakawa K; Ross MI; Eton O; Swanson DA; Itoh K
Cancer Immunol Immunother; 1993 Nov; 37(6):392-9. PubMed ID: 8242664
[TBL] [Abstract][Full Text] [Related]
54. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma.
Gaudin C; Kremer F; Angevin E; Scott V; Triebel F
J Immunol; 1999 Feb; 162(3):1730-8. PubMed ID: 9973436
[TBL] [Abstract][Full Text] [Related]
55. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
[TBL] [Abstract][Full Text] [Related]
56. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
57. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
[No Abstract] [Full Text] [Related]
58. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
[TBL] [Abstract][Full Text] [Related]
59. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
60. Immune inhibitory effects of renal cell carcinoma extract on lectin and alloantigen-induced peripheral blood and tumor infiltrating lymphocyte blastogenesis.
Shabtai M; Ye H; Kono K; Takayam T; Terashima K; Tsukuda K; Frischer Z; Waltzer WC; Malinowski K
Urol Oncol; 2003; 21(1):27-32. PubMed ID: 12684124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
